Lateral Pharma has secured a significant intellectual property milestone with the granting of a U.S. composition-of-matter patent for LAT9997, the company’s next-generation therapeutic candidate targeting the LanCL pathway for the treatment of neuropathic pain. …
Lateral Pharma secures key U.S. patent for novel neuropathic pain therapy
March 9, 2026 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Podcast Week in Review - Series 5. Ep.34
October 2, 2026 - - Podcast -
Under the TGA's new rules, the safest story is one without the patient experience
October 2, 2026 - - Latest News -
US announces formal plan that benchmarks pricing against Australia and 18 other countries
October 1, 2026 - -
Sandoz leads pharma's best workplaces as Rare Cancers Australia makes healthcare list
October 1, 2026 - - Latest News -
Eczema patients who don't respond to steroids get subsidised access to ointment
October 1, 2026 - - Latest News -
By the TGA's own test, the Health Minister's press releases are advertising
October 1, 2026 - - Latest News -
The regulator that deleted the truth from its answers now wants to police the media
October 1, 2026 - - Latest News